uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights

NodeGuardian · 2026-04-04T05:53:53+00:00

Robbins LLP is alerting investors about a class action lawsuit against uniQure N.V. for allegedly misleading statements about FDA approval for AMT-130, leading to a sharp stock price decline. Shareholders can contact Robbins LLP regarding their rights by April 13, 2026.

NodeGuardian

2026-04-04 05:53:53

Abstract generation in progress

Robbins LLP is reminding investors of a class action lawsuit filed against uniQure N.V. (NASDAQ: QURE) for alleged misleading statements regarding the FDA approval process for its drug candidate, AMT-130. The lawsuit covers investors who purchased shares between September 24, 2025, and October 31, 2025, during which the company allegedly failed to disclose issues with FDA approval for its pivotal study design. Following the FDA’s feedback disputing the adequacy of the study data, uniQure’s stock price plummeted by over 49%, and shareholders are encouraged to contact Robbins LLP to learn about their rights and potentially serve as lead plaintiff by April 13, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes